House Members Object To Senate Adding Supplement MPL Proposal In FDA User Fee Bill
Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.
You may also be interested in...
With Congress considering mandatory supplement product listing as requested by FDA, trade group asks NIH’s Office of Dietary Supplements to share its experience building and maintaining its label database.
Cosmetics Industry Still Committed To Reg Modernization, But FDA User-Fee Reauthorization May Not Be Vehicle
A “clean” FDA user-fee reauthorization bill – minus cosmetics modernization provisions – could be the likeliest way forward with user-fee program funding set to elapse at the end of September, a PCPC rep suggested in an email to HBW Insight.
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.